

If the following information is not complete, correct, or legible, the SA process can be delayed.

Please use one form per member.

Physician Administered Drug: This form is only to be used for members obtaining the medication from a pharmacy through billing the pharmacy benefit at point-of-sale. Please refer to [Appendix B: Physician Administered Drug Criteria](#) for members/providers who will obtain the medication through the medical benefit.

MEMBER INFORMATION

Last Name:

First Name:

Medicaid ID Number:

Date of Birth:

Weight in Kilograms: _____

PRESCRIBER INFORMATION

Last Name:

First Name:

NPI Number:

Phone Number:

Fax Number:

DRUG INFORMATION

Drug Name/Form: _____

Strength: _____

Dosing Frequency: _____

Length of Therapy: _____

Quantity per Day: _____

The Virginia Department of Medical Assistance Services considers the use of concomitant therapy with Cinqair®, Dupixent®, Exdensur®, Fasentra®, Nucala®, Tezspire™ and Xolair® to be experimental and investigational. Safety and efficacy of these combinations have **NOT** been established and will **NOT** be permitted.

(Form continued on next page.)

Member's Last Name:

Member's First Name:

DIAGNOSIS AND MEDICAL INFORMATION

For severe* asthma initial approval, complete the following questions to receive a 6-month approval:

1. Is the member 12 years of age or older? **AND**
 Yes No
2. Does the member have a diagnosis of severe* asthma? **AND**
 Yes No
3. Does the member have asthma with an eosinophilic phenotype defined as baseline blood eosinophils \geq 150 cells/ μ L? **AND**
 Yes No
4. Will coadministration with another monoclonal antibody be avoided (e.g., omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, tezepelumab-ekko)? **AND**
 Yes No
5. Will this medication be used for add-on maintenance treatment in members regularly receiving **both** of the following (unless otherwise contraindicated):
 - Medium- to high-dose inhaled corticosteroids; **AND**
 - An additional controller medication (e.g., long-acting beta agonist, leukotriene modifiers)? Yes No
6. Has the member had two or more exacerbations in the previous year requiring oral or injectable corticosteroid treatment (in addition to the regular maintenance therapy defined above) **or** one exacerbation resulting in a hospitalization? **AND**
 Yes No
7. Does the member have at least one of the following for assessment of clinical status:
 - Use of systemic corticosteroids
 - Use of inhaled corticosteroids
 - Number of hospitalizations, ER visits, or unscheduled visits to healthcare provider due to condition
 - Forced expiratory volume in 1 second (FEV₁)? **AND** Yes No
8. Has the member tried and failed two preferred agents listed on the PDL where applicable for the requested product's intended use?
 Yes No

(Form continued on next page.)

Member's Last Name:

Member's First Name:

For severe asthma renewal, complete the following questions to receive a 12-month approval:

9. Does the member have improvement in asthma symptoms or asthma exacerbations as evidenced by decrease in one or more of the following:

- Use of systemic corticosteroids
- Hospitalizations
- ER visits
- Unscheduled visits to healthcare provider
- Improvement from baseline in forced expiratory volume in 1 second (FEV₁)?

Yes No

*** Components of severity for classifying asthma as *severe* may include any of the following (not all-inclusive):**

- Asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA
- Asthma that requires high-dose ICS-LABA to prevent it from being uncontrolled
- Symptoms throughout the day
- Nighttime awakenings, often 7 times/week
- SABA use for symptom control occurs several times per day
- Extremely limited normal activities
- Lung function (percent predicted FEV₁) < 60%
- Exacerbations requiring oral systemic corticosteroids are generally more frequent and intense relative to moderate asthma

Prescriber Signature (Required)

Date

By signature, the physician confirms the above information is accurate and verifiable by member records.

Please include ALL requested information; incomplete forms will delay the SA process.

Submission of documentation does NOT guarantee coverage by the Department of Medical Assistance Services.

Fax this form to 1-866-940-7328

Pharmacy PA Call Center 1-800-310-6826

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.